Eli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, but a new study in people who have failed earlier migraine therapies could help.

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that ...